RxDoctor Payments Data

Elisa Barcalow

Family · Steubenville, OHNPI 1235508359

Payments from drug & device makers

$4,937in general payments, 2019–2025

Across 320 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$793
  • AstraZeneca$781
  • Novo Nordisk$529
  • Boehringer Ingelheim$164
  • Pfizer$149
  • plus $1K from 33 others

What the payments were for

  • Food & beverage$4,929100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,937 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$23,551
Medicare patients
121
Services billed
511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept14$107,878
OzempicSemaglutide67$79,379
MounjaroTirzepatide56$67,127
TrulicityDulaglutide20$29,053
JanuviaSitagliptin Phosphate25$27,734
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$19,906
XareltoRivaroxaban25$18,549
FarxigaDapagliflozin Propanediol29$16,424
JardianceEmpagliflozin27$15,953
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$13,528
QuliptaAtogepant13$13,397
Tresiba Flextouch U-200Insulin Degludec18$12,206
Repatha SyringeEvolocumab17$10,553
Tresiba Flextouch U-100Insulin Degludec21$10,082
Zolmitriptan14$8,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$121$96,18076 claims
Novo NordiskOzempic$529$79,37967 claims
MerckJanuvia, Dulera$113$34,09544 claims
AstraZenecaFarxiga, Breztri Aerosphere$781$29,95244 claims
GSKTrelegy Ellipta$108$19,90634 claims
Johnson & JohnsonXarelto$25$18,54925 claims
Boehringer IngelheimJardiance$164$15,95327 claims
AbbVieQulipta, Synthroid$793$14,90948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Steubenville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →